LABP - Landos Biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5700
+0.3100 (+9.51%)
As of 03:54PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.2600
Open3.0900
Bid3.5100 x 900
Ask3.5900 x 1000
Day's Range3.1950 - 3.6300
52 Week Range2.1100 - 13.7000
Volume54,028
Avg. Volume20,925
Market Cap11.127M
Beta (5Y Monthly)-1.15
PE Ratio (TTM)N/A
EPS (TTM)-6.7600
Earnings DateAug 09, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LABP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

    NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY. Gregory Oakes, Chief Executive Officer, and Fabio Cataldi, Chief Medical Officer, will provide a corporate update, including highlights of the NX-13 program and the recent la

  • GlobeNewswire

    Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

    NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos. “Dr. Batycky has a proven track record, and we

  • GlobeNewswire

    Landos Biopharma Announces 1-for-10 Reverse Stock Split

    NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on May 26, 2023 und

  • GlobeNewswire

    UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

    NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue

  • GlobeNewswire

    Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

    NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue

  • GlobeNewswire

    Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

    On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the fourth quar

  • GlobeNewswire

    Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

    Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second Quarter of 2023NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the transfer of its LANCL po

  • GlobeNewswire

    Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

    Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization do

  • GlobeNewswire

    Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

    Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runw

  • GlobeNewswire

    Landos Biopharma Announces $16.7 Million Private Placement Financing

    NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos’ largest

  • GlobeNewswire

    Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

    On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming WeeksNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 an

  • Simply Wall St.

    We're A Little Worried About Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • GlobeNewswire

    Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

    Dr. Cataldi Brings Over Two Decades of Clinical Research and Drug Development Experience in Gastroenterology and ImmunologyNEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Company’s Chief Medical Officer, effective September 5, 2022. “We are thrilled to welcome Fabio to Landos, and look f

  • Benzinga

    Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming 'Pipeline Reset'

    Raymond James downgraded Landos Biopharma Inc (NASDAQ: LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13 Phase 1b data in ulcerative colitis (UC). The analyst's rating change is driven by: Unclear strategy for omilancor in UC/Crohn's Disease (CD) (formulation optimization needed to improve solubility). Lack of conviction on NX-13's early efficacy data in UC until an adequately powered study is more clearly demonstrative of efficacy. The LAPB management t

  • GlobeNewswire

    Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

    Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to Complete Comprehensive Review of Clinical Development Plans Later this Year NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical c

  • GlobeNewswire

    Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

    NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clini

  • GlobeNewswire

    Landos Names Gregory Oakes President and Chief Executive Officer

    Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that Gregory Oakes has been named President and Chief Executive Officer, and has been